Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013

Emerg Infect Dis. 2014 May;20(5):913-5. doi: 10.3201/eid2005.131766.
No abstract available

Keywords: Belgium; CD20 B-cell antigen; coxsackievirus; coxsackievirus A16; encephalitis; enterovirus; monoclonal antibody; obinutuzumab; viruses.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Belgium
  • Encephalitis, Viral / diagnosis
  • Encephalitis, Viral / drug therapy
  • Encephalitis, Viral / etiology*
  • Enterovirus / classification*
  • Enterovirus / genetics
  • Enterovirus Infections / diagnosis
  • Enterovirus Infections / drug therapy
  • Enterovirus Infections / etiology*
  • Female
  • Humans
  • Immunoglobulins, Intravenous
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / drug therapy
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Immunoglobulins, Intravenous
  • obinutuzumab